Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

AMPHNYSE / NASDAQHealthcareSmall cap

$28.25+$0.14 (+0.5%)

Last close · Data as of Nov 20, 2026

Market cap
$824.5M
P/E
8.4x
EV / EBITDA
6.2x
Revenue
$719.9M
Net margin
13.6%
ROCE
9.5%

+11.4% over the last year

Amphastar Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+8.9%
3M
+30.3%
6M
+56.3%
1Y
+11.4%
5Y
+37.7%

52-week range

Day change +$0.14 (+0.5%) from $28 to $28 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AMPH, bought on each weekday since 2021.

News & filings

What Amphastar Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating margin fell for three years, from 30.6% to 19.5%.

Strengths (1)

  • Free cash flow in fiscal 2025 equals 14.4% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

Read moreShow less

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector
Healthcare
Shares outstanding
46.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$824.5M
P/E
8.4x
P/B
1.0x
EV / EBITDA
6.2x
EV / Sales
1.8x
P/S
1.1x
52-week high
$29.71
52-week low
$16.87

Profitability

Operating margin
19.5%
Net margin
13.6%
EBITDA margin
29.5%
ROE
12.4%
ROCE
9.5%
ROA
6.0%
Asset turnover
0.44

Growth

Revenue
$719.9M
Revenue growth, 1Y
-1.7%
Revenue CAGR, 3Y
13.0%
Net profit growth, 1Y
-38.5%
Free cash flow
$119.0M

Solvency

Current ratio
4.02
Debt / Equity
0.83
Debt / Assets
0.40
CFO / Net profit
1.59
Cash / Market cap
20.6%

Where the revenue went

Of every $100 of FY2025 revenue, $14 was left as net income.

Amphastar Pharmaceuticals, Inc. income statement flow, FY2025
Amphastar Pharmaceuticals, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$363.8M
RevenueGross profit$356.1M
Gross profitResearch and development$85.8M
Gross profitSelling, general and administrative$129.8M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$140.4M
Operating incomePretax income$123.6M
Operating incomeInterest and other expense$16.8M
Pretax incomeTax and other$25.5M
Pretax incomeNet income$98.1M

Revenue and net profit

Revenue fell 1.7% in FY2025; net profit is the dashed line.

Amphastar Pharmaceuticals, Inc. revenue and net profit by fiscal year
Amphastar Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$499.0M$91.4M
FY2023$644.4M$137.5M
FY2024$732.0M$159.5M
FY2025$719.9M$98.1M

Cash flows

FY2025: $156.1M from operations, $119.0M free after investment (dashed).

Amphastar Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Amphastar Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$89.2M$65.1M
FY2023$183.5M$145.3M
FY2024$213.4M$172.3M
FY2025$156.1M$119.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$719.9M-1.7%1Y
EBITDA
$212.3M-23.4%1Y
Net profit
$98.1M-38.5%1Y
Cash from operations
$156.1M-26.8%1Y
Free cash flow
$119.0M-31.0%1Y
Revenue CAGR, 3Y
13.0%
Net profit CAGR, 3Y
2.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$719.9M$212.3M$98.1M$119.0M12.4%-1.7%-38.5%

Monthly returns

Month-by-month returns of AMPH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.6B
Liabilities$840.5M
Equity$788.8M
Paid-in capital$535.4M
Retained earnings$666.9M
Treasury stock$408.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AMPH highlighted.

P/E against peers

AMPH trades at 8.4x earnings against a peer median of -6.4x.

  1. Amphastar Pharmaceuticals, Inc. (this company)8.4x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc., Replimune Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Amphastar Pharmaceuticals, Inc.AMPHthis company$824.5M8.4x1.0x12.4%6.2x
Theravance Biopharma, Inc.TBPH$843.9M8.0x2.8x35.7%5.3x
Janux Therapeutics, Inc.JANX$839.1M-7.4x0.9x-11.9%-5.2x
ORIC Pharmaceuticals, Inc.ORIC$830.2M-6.4x2.2x-33.7%-5.6x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Sana Biotechnology, Inc.SANA$823.7M-3.4x5.1x-151.8%-4.3x
Replimune Group, Inc.REPL$815.0M-3.3x2.0x-59.5%-3.3x
Esperion Therapeutics, Inc.ESPR$805.8M——7.5%13.9x
Lumexa Imaging Holdings, Inc.LMRI$791.7M-16.8x1.4x-8.0%12.0x
Peer median—-6.4x2.2x-10.1%-3.8x

Year-to-date ROI

AMPH since 1 January, against earlier years.

Historical volatility

AMPH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Amphastar Pharmaceuticals, Inc. operating margin by fiscal year
Amphastar Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY202221.5%
FY202330.6%
FY202428.1%
FY202519.5%
LineFY2025
Cost of revenueCost Of Revenue$363.8M
Gross profitGross Profit$356.1M
Operating expensesOperating Expense$215.7M
Research and developmentResearch And Development$85.8M
Total expensesTotal Expenses$579.5M
Pretax incomePretax Income$123.6M

Learn while you research

Academy chapters picked for Amphastar Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.4 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →